Latest Conference Articles

January 21st 2022, 9:20pm

Gastrointestinal Cancers Symposium (ASCO GI)

Nivolumab plus chemotherapy demonstrated a durable survival benefit for patients with gastric or gastroesophageal junction cancer, according to updated findings from the CheckMate 649 trial.

January 21st 2022, 8:40pm

Gastrointestinal Cancers Symposium (ASCO GI)

Sintilimab plus standard-of-care chemotherapy failed to demonstrate a significant improvement in overall survival and progression-free survival vs standard-of-care chemotherapy alone but did result in an improved objective response rate in patients with metastatic or recurrent pancreatic adenocarcinoma, according to findings from the phase 3 CISPD3 trial.

January 21st 2022, 8:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.

January 21st 2022, 6:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations.

January 20th 2022, 11:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.

January 20th 2022, 11:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events in patients with advanced gastric cancer who are receiving single-agent nivolumab.

January 20th 2022, 10:11pm

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited a pathologic complete response rate of 59% in patients with resectable microsatellite instable or mismatch repair deficient oeso-gastric junction adenocarcinoma.

January 20th 2022, 9:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

January 20th 2022, 9:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer.

January 18th 2022, 10:00pm

Memorial Sloan Kettering Cancer Center

The combination of durvalumab and tremelimumab demonstrated a significant improvement in overall survival vs sorafenib as frontline therapy in patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 HIMALAYA trial.

January 18th 2022, 10:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer.

December 15th 2021, 9:45pm

ASH Annual Meeting and Exposition

The investigational bispecific antibody APVO436 demonstrated tolerability with encouraging anti-neoplastic efficacy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome, according to updated findings from an ongoing phase 1 trial.

December 15th 2021, 9:25pm

ASH Annual Meeting and Exposition

Elevated amphiregulin was associated with increased mortality risk in acute graft–versus-host-disease, according to a sample of 2 prospective clinical trials showed.

December 15th 2021, 9:20pm

ASH Annual Meeting and Exposition

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone continued to elicit improved outcomes vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the extended 2-year follow-up analysis of the phase 2 GRIFFIN trial.

December 15th 2021, 8:52pm

ASH Annual Meeting and Exposition

Treatment with the CD123- and CD3-engaging bispecific antibody APVO436 caused cytokine release syndrome in approximately 1 of 5 patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome but was generally well managed with steroids.

December 15th 2021, 1:42pm

ASH Annual Meeting and Exposition

Patients with relapsed or refractory large B-cell lymphoma experienced better quality of life when they received second-line treatment with lisocabtagene maraleucel vs standard of care.

December 15th 2021, 1:18pm

ASH Annual Meeting and Exposition

A single infusion of ciltacabtagene autoleucel produced an overall response rate of 95% in patients with multiple myeloma who had received a median of 2 prior lines of treatment and who were refractory to lenalidomide.

December 14th 2021, 11:38pm

ASH Annual Meeting and Exposition

The utilization of oral azacitidine as maintenance treatment in patients with acute myeloid leukemia in first remission following intensive chemotherapy continued to showcase a survival benefit over placebo.

December 14th 2021, 11:07pm

ASH Annual Meeting and Exposition

Data from a longer follow-up analysis of the phase 1/2 CARTITUDE-1 trial demonstrated that all evaluated subgroups of patients with relapsed/refractory multiple myeloma maintained durable responses with ciltacabtagene autoleucel.

December 14th 2021, 10:51pm

ASH Annual Meeting and Exposition

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.